Treace Medical (TMCI) Fundamental Analysis: Revenue, Earnings & Valuation

0.83 / 10

Underperform

Fundamental breakdown reveals concerning profile (0.8/10). Supportive elements: Profit-MV and Cash-MV, offset by weaknesses in Revenue-MV and Net income-Revenue. This suggests constrained positioning.

Analysis Checks(4/10)

Revenue-MV

Value0.76

Score0/3

Weight43.87%

1M Return-6.06%

ROA (%)

Value-28.95

Score1/3

Weight6.41%

1M Return-0.78%

Net cash flow from operating activities / Operating revenue (%)

Value-7.51

Score3/3

Weight-14.75%

1M Return1.44%

Profit-MV

Value0.62

Score2/3

Weight-10.60%

1M Return1.09%

Net income-Revenue

Value-0.05

Score1/3

Weight21.94%

1M Return-2.75%

Total profit / EBIT (%)

Value104.50

Score0/3

Weight28.57%

1M Return-4.05%

Annualized net profit margin on total assets (%)

Value-28.95

Score1/3

Weight6.41%

1M Return-0.78%

EBIT / Total operating revenue (%)

Value-26.55

Score2/3

Weight4.76%

1M Return-0.56%

Asset-MV

Value-0.72

Score1/3

Weight31.92%

1M Return-4.33%

Cash-MV

Value0.01

Score2/3

Weight-18.53%

1M Return1.75%

Is TMCI undervalued or overvalued?

TMCI scores 0.83/10 on fundamentals and holds a Premium valuation at present. Backed by its -58.94% ROE, -27.74% net margin, -1.59 P/E ratio, 1.07 P/B ratio, and -3.33% earnings growth, these metrics solidify its Underperform investment rating.